Peptide Based Therapeutics For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Peptide therapeutics represent a rapidly growing class of drugs for neurodegenerative diseases, bridging the gap between small molecules and large biologics. Peptides offer high specificity for target engagement while potentially avoiding some limitations of both approaches.[1] This page covers peptide drugs and peptide-based approaches in development for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders. [1]
The global peptide therapeutics market is projected to reach $50 billion by 2025, with neurodegenerative applications representing a significant growth area.[2] Unlike small molecules that often lack specificity, peptides can be designed to target protein-protein interactions central to neurodegeneration pathology. [2]
Cell-penetrating peptides enable delivery of therapeutic cargo across the blood-brain barrier (BBB) and into target cells.[3] [3]
| Peptide | Origin | Mechanism | Applications | [4]
|---------|--------|-----------|--------------| [5]
| TAT (Trans-Activator of Transcription) | HIV-1 | Direct membrane penetration | Protein delivery, imaging | [6]
| Penetratin | Antennapedia homeodomain | Endocytosis-mediated | siRNA delivery | [7]
| Polyarginine (R9) | Synthetic | Electrostatic interaction | Drug conjugation | [8]
| Transportan | Chimeric | Multiple mechanisms | Cargo delivery | [9]
CPPs can deliver neuroprotective proteins, antisense oligonucleotides, and small molecules directly to neurons and glia.[4] [10]
Synthetic peptides that mimic neurotrophic factors offer advantages over full-length proteins including improved stability and BBB penetration.[5] [11]
Designed to bind, inhibit aggregation, or clear pathological protein aggregates.[10] [12]
| Target | Peptide Approach | Status | [13]
|--------|-----------------|--------| [14]
| Aβ | KLVFF-derived inhibitors | Preclinical/Clinical | [15]
| Tau | PHF6-blocking peptides | Preclinical | [16]
| α-synuclein | Aggregation blockers | Preclinical | [17]
| TDP-43 | RNA-binding domain peptides | Research | [18]
Some AMPs exhibit neuroprotective and immunomodulatory effects:[11] [19]
Peptide Vaccines (Active Immunization)
Anti-Aβ Peptide Approaches
BACE1 Inhibitor Peptides
Neuroprotective Peptides
α-Synuclein Targeting Peptides
Neurotrophic Peptide Delivery
Gene Delivery Peptides
SOD1-Mimetic Peptides
Anti-Excitotoxicity Peptides
TDP-43 Targeting
| Advantage | Description |
|---|---|
| High specificity | Target specific protein-protein interactions |
| Low tissue accumulation | Reduced risk of long-term toxicity |
| Reduced off-target effects | Clean pharmacological profile |
| Chemical versatility | Multiple modification strategies available |
| BBB penetration | CPPs enable CNS delivery |
| Biocompatibility | Often derived from endogenous sequences |
| Challenge | Mitigation Strategy |
|---|---|
| Short half-life | PEGylation, D-amino acids, cyclization |
| Poor oral bioavailability | Parenteral, intranasal, or transdermal routes |
| High manufacturing costs | Recombinant production, solid-phase synthesis optimization |
| Potential immunogenicity | Humanized sequences, PEGylation |
| Limited tissue distribution | Targeted delivery systems, CPPs |
| Route | Advantages | Challenges |
|---|---|---|
| Subcutaneous | Self-administration, sustained release | Limited CNS penetration |
| Intranasal | Direct nose-to-brain delivery | Dose volume limitations |
| Intravenous | Rapid systemic distribution | Short half-life, degradation |
| Intrathecal | Direct CSF access | Invasive, infection risk |
| Convection-enhanced | Broad brain distribution | Highly invasive |
Cyclization improves metabolic stability and binding affinity:[18]
Hydrocarbon-stapled peptides show improved helicity, protease resistance, and cell penetration.[19] Applications include:
Peptides conjugated to small molecule drugs for targeted delivery:[20]
| Peptide | Target | Disease | Phase | Sponsor |
|---|---|---|---|---|
| CAD106 | Aβ | AD | Phase 2 | Novartis |
| ACI-35 | Aβ | AD | Phase 2 | AC Immune |
| Semaglutide | GLP-1R | AD | Phase 3 | Novo Nordisk |
| Liraglutide | GLP-1R | PD | Phase 2 | ELND |
The study of Peptide Based Therapeutics For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lau JL, Dunn MK. Therapeutic peptides: Histories, perspectives, and the future. Bioorg Med Chem. 2018. ↩︎
Guidotti G, et al. Cell-penetrating peptides: Overview and future directions. Trends Biotechnol. 2017. ↩︎
Wang H, et al. Cell-penetrating peptide-based delivery systems for neurodegenerative diseases. AAPS J. 2015. ↩︎
O'Leary PD, Hughes RA. Design of potent, minimally neurotoxic peptides based on BDNF. J Biol Chem. 2003. ↩︎
Massa SM, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration. J Clin Invest. 2010. ↩︎
Bruno MA, et al. NGF-based peptide mimetics as therapeutic agents in Alzheimer's disease. Neurodegener Dis. 2018. ↩︎
Park JH, et al. GDNF-mimetic peptides: A promising therapeutic approach for Parkinson's disease. Neuropharmacology. 2021. ↩︎
Ren X, et al. CDNF and MANF: Emerging neurotrophic factors in Parkinson's disease. Neurosci Bull. 2022. ↩︎
Stöhr J, et al. Peptide-based inhibitors of amyloid-β aggregation. Biochemistry. 2017. ↩︎
Leung C, et al. Antimicrobial peptides in neurodegeneration. Int J Mol Sci. 2020. ↩︎
Winblad B, et al. CAD106: Active Aβ immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2012. ↩︎
Wiesehan K, et al. D-peptides as inhibitors of Aβ aggregation. ChemBioChem. 2003. ↩︎
Egan MF, et al. BACE inhibition in early Alzheimer's disease. N Engl J Med. 2019. ↩︎
Gozes I, et al. NAP (davunetide) in clinical trials for neurodegenerative diseases. J Mol Neurosci. 2016. ↩︎
Cheruvara H, et al. Peptide inhibitors of α-synuclein aggregation. J Mol Biol. 2020. ↩︎
Boll MC, et al. SOD1-mimetic peptides in ALS therapy. Neurosci Lett. 2018. ↩︎
Zorzi A, et al. Cyclic peptide therapeutics: A review. J Med Chem. 2017. ↩︎
Verdine GL, Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol. 2012. ↩︎
Cooper BM, et al. Peptides as a platform for targeted therapeutics. Nat Rev Drug Discov. 2021. ↩︎